



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated August 06, 2019**

To,  
National Stock Exchange of India Limited,  
BSE Limited  
**Symbol: GRANULES Scrip Code: 532482**

**Sub: Granules Pharmaceuticals, Inc. received US FDA approval for Amphetamine Sulfate Tablets**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc., a wholly owned foreign subsidiary of Granules India Limited for Amphetamine Sulfate Tablets USP 5 mg and 10 mg. It is bioequivalent to the reference listed drug product (RLD), Evekeo Tablets, 5 mg and 10 mg, of Arbor Pharmaceuticals, LLC.

Amphetamine Sulfate tablets is a central nervous system stimulant used to treat sleep disorder, increase attention, decrease impulsiveness and hyperactivity in patients with Attention Deficit Hyperactivity Disorder (ADHD).

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

**FOR GRANULES INDIA LIMITED**

*Chaitanya Tummala*

**CHAITANYA TUMMALA  
COMPANY SECRETARY  
COMPLIANCE OFFICER**

